coronary artery disease
Conditions
Interventions
Treatment group:On the basis of routine treatment of western medicine, take Xinpi Tongzhi prescription twice a day, 1 bag each time, and take it with warm boiled water.
Control group:On the basis of routine treatment of western medicine, take the placebo of Xinpi Tongzhi prescription twice a day, 1 bag each time, and take warm boiled water.
Sponsors
Xiyuan Hospital of Chinese Academy of traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) 18 years old = age = 75 years old, regardless of gender. (2) Coronary angiography showed coronary artery small vessel lesions (lumen diameter = 2.75mm), stenosis = 70%. (3) Drug balloon dilatation within 1 year. (4) in accordance with the diagnostic criteria of heart-spleen-qi deficiency and blood stasis syndrome in traditional Chinese medicine. (5) those who sign the informed consent form will be tested voluntarily.
Exclusion criteria
Exclusion criteria: (1) it is difficult to control decompensated heart failure, acute myocarditis, pericardial disease, valvular heart disease, primary cardiomyopathy and severe left ventricular hypertrophy. (2) recurrent patients with malignant arrhythmias (ventricular tachycardia, supraventricular arrhythmias affecting hemodynamics, atrioventricular block above ? °). (3) complicated with malignant hypertension (systolic blood pressure = 200mmHg, or diastolic blood pressure = 120mmHg) or severe hypotension (diastolic blood pressure < 90mmHg). (4) patients with acute cerebrovascular disease, severe primary diseases such as lung, liver, kidney, hematopoietic system, malignant tumor, mental illness and severe neurosis. (5) pregnant or preparing pregnant women, lactating women and those who are allergic to known ingredients of research drugs. (6) those who have participated or are participating in other clinical trials in the past three months. (7) patients who need continuous mechanical auxiliary therapy after successful interventional therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Peak VO2, METs;Primary end point index (all-cause death, stroke, non-fatal myocardial infarction, emergency revascularization);Secondary end point index (due to rehospitalization of coronary heart disease, cardiac insufficiency, malignant arrhythmia and other thrombotic complications); | — |
Secondary
| Measure | Time frame |
|---|---|
| Seattle angina pectoris scale;Score of blood stasis syndrome of coronary heart disease;Glycosylated hemoglobin;Low density lipoprotein cholesterol;Inflammatory index; | — |
Countries
China
Contacts
Public ContactJianpeng Du
Xiyuan Hospital, China Academy of Chinese Medical Sciences
Outcome results
None listed